期刊文献+

索拉非尼治疗晚期原发性肝癌的并发症及相关处理 被引量:3

下载PDF
导出
摘要 目的分析使用索拉非尼治疗晚期原发性肝癌的并发症,探讨临床处理措施及疗效。方法回顾性分析2008年2月~2009年7月,25例晚期原发性肝癌患者使用索拉非尼治疗的资料,记录各种并发症的发生率、类型、临床处理及疗效。结果腹泻、手足皮肤反应及体重减轻、脱发为最常见并发症。4例患者因并发症予以下调药物剂量,经临床治疗后恢复药物剂量。无患者因并发症停药。结论使用索拉非尼治疗晚期PHC的过程中出现的各种不良发应均可防、可控、可治疗。
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第6期1437-1438,共2页 Journal of Southern Medical University
基金 深圳市医学重点学科项目
  • 相关文献

参考文献5

  • 1Stewart BW, Kleihues P. World Cancer Report [M]. Lyon: IARC, 2003: 1-351.
  • 2陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31. 被引量:93
  • 3National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE) Available at http://ctep.cancer. gov/forms/ctcae v3.pdf. Accessed March 20, 2008.
  • 4Scott MW, Christopher C, Li YT, et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64: 7099-109.
  • 5Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma(HCC) [J]. J Clin Oncol, 2007, Supp118: LBA 1.

二级参考文献15

  • 1陈建国.PooledAnalysis──流行病学研究中的一个新方法[J].中华流行病学杂志,1994,15(4):231-233. 被引量:3
  • 2中华人民共和国恶性肿瘤地图集编辑委员会.中华人民共和国恶性肿瘤地图集[M].上海:中华地图学社出版,1979.1-99.
  • 3Stewart BW, Kleihues P. World Cancer Report[M].Lyon:IARC, 2003.1-351.
  • 4Ferlay J, Bray F, Pisani P, et al. Globocan 2000: Cancer incidence, mortality and prevalence worldwide.IARC CancerBase No.5[DB/CD]. Lyon: IARC, 2001.
  • 5Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents,Ⅷ. IARC Sci Publ No.155[M].Lyon:IARC, 2002.212-231.
  • 6Parkin DM, Whelan SL, Ferlay J, et al. Electronic database of cancer incidence in five continents,Ⅷ [DB/CD].Lyon: IARC, 2002.
  • 7Wang QS.Cancer registration in China [J].Asian Pacific J Cancer Prev,2001,2(S):3-8.
  • 8Thomas TK, Qian GS, Chen JG, et al. Translational strategies for cancer prevention in liver [J]. Nat Rev Cancer,2003,3(5): 321-329.
  • 9Stward BW,Kleihues P.World Cancer Report[M].Lyon:IARC,2003:1-351.
  • 10Ferlay J,BrayF, Pisani P,et al.Globocan 2000:Cancer incidence,mortality and prevalence worldwide.IARC Cancer Base No5[DB/CD].Lyon:IARC.2001.

共引文献92

同被引文献26

  • 1陈建国,宋新明.中国肝癌发病水平的估算及分析[J].中国肿瘤,2005,14(1):28-31. 被引量:93
  • 2陆景峰.原发性肝癌经TACE术后并发肺转移13例临床分析[J].肿瘤研究与临床,2004,16(6):405-406. 被引量:4
  • 3Ten Cate H,Timmerman J J, Levi M. The pathophysiology of dissemina- ted intrvascular coagulation [ J]. Thromb Haemost, 1999,82 : 713.,.
  • 4Ma Lw, Jia TZ. Optimal management for hepatcellular carcinoma [ J ]. chin J Cancer Prey Treat,2005,12(6) :471.
  • 5Bidofi P, Stani SC, Mariani L, et al. Phase I study of escalating doses of oxafiplatin in combination with fixed doae gemcitabine in patients with non -small cell lung cancer[ J ]. Lung Cancer,2004,43 (2) :203.
  • 6Franciosi V, Barbieri R, Aitini E, et al, gemcitabine and oxaliplatin : a safe ahd active regimen inn poor prognosis advanced non - small cell lung cancer patients[ J]. Lung Cancer,2003,41 ( 1 ) :101.
  • 7Ulrichpur H, Kornek GV, Fiebiger W,et al. Treatment of advanced hep- atocellular carcinoma with biweekly highdosegemcitabine [ J ]. Oncolo- gy,2001,60(4) :313.
  • 8Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for pa- tients with advanced hepatocellular carcinoma using two different sched- ules[ J ]. Cancer,2003,98 ( 12 ) :2664.
  • 9Lin CL, Kao JH. Optimal management of hepatocellular carcinoma : challenges and opportunities [ J ]. J Gastroenterol Hepatol, 2010, 25(8) :1336-1338.
  • 10Bidoli P, Stani SC, Mariani L, et al. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer [ J ]. Lung Cancer, 2004,43 (2) :203 -208.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部